Natera Reports Strong Q1 Revenue Growth Amidst Increased Net Loss and Significant Legal Verdict

summarizeSummary

Natera reported strong 38.8% year-over-year revenue growth in Q1 2026, but also an increased net loss and a significant $292.5 million jury verdict against the company in a false advertising lawsuit, which the company plans to appeal.

check_boxKey Events

• Strong Revenue Growth

  Total revenues for the first quarter of 2026 increased by 38.8% year-over-year to $696.6 million, primarily driven by product revenues from Signatera, Panorama, and Horizon tests.

• Increased Net Loss

  The company reported a net loss of $85.1 million for Q1 2026, compared to a net loss of $66.9 million in Q1 2025. This was influenced by a 63.2% surge in research and development expenses and a 22.9% increase in selling, general, and administrative expenses.

• Significant Legal Liability from Guardant Case

  A jury returned a verdict finding Natera liable for false advertising in a lawsuit filed by Guardant Health, Inc., awarding damages of $292.5 million. Natera plans to appeal this judgment. This follows a prior positive outcome in the CareDx patent case where Natera was found not liable for damages.

• Executive 10b5-1 Selling Plans Adopted

  CEO Steve Chapman modified a Rule 10b5-1 Trading Plan for the potential sale of 180,643 shares, and Executive Chairman Matthew Rabinowitz adopted a plan for the potential sale of up to 100,000 shares. These are pre-planned sales, with a significant portion of the CEO's plan being performance-based.

auto_awesomeAnalysis

Natera's first-quarter results show robust revenue growth, driven by increased test volumes, which is a positive operational signal. However, this growth was accompanied by a notable increase in net loss, primarily due to higher operating expenses and a significant legal judgment. The $292.5 million jury verdict against the company in the Guardant case represents a substantial financial liability, even with a planned appeal, and introduces considerable uncertainty. While the favorable outcome in the CareDx patent case is a positive development, the overall legal landscape remains challenging. The establishment of 10b5-1 selling plans by key executives, though pre-planned, could add to selling pressure. Investors should weigh the strong top-line performance against the escalating losses and the material legal risks.